A clinical hold on an Intellia Therapeutics CRISPR drug trial has been lifted by the FDA, although it is reported that a hold was also placed on two other Intellia CRISPR trials. The company has also launched a public stock offering and reported positive phase 3 trial results for a therapy. The status of Intellia's CRISPR drug studies appears to be uncertain, with some trials proceeding and others paused due to safety concerns.